These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 27282159)

  • 1. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Boulton DW
    Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
    Upreti VV; Boulton DW; Li L; Ching A; Su H; Lacreta FP; Patel CG
    Br J Clin Pharmacol; 2011 Jul; 72(1):92-102. PubMed ID: 21651615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Campbell RK
    Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
    Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
    Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK; Drayna CC; McDermott MT
    Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Tahrani AA; Piya MK; Barnett AH
    Adv Ther; 2009 Mar; 26(3):249-62. PubMed ID: 19330494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
    Lam S; Saad M
    Cardiol Rev; 2010; 18(4):213-7. PubMed ID: 20539105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
    Jain R
    Adv Ther; 2015 Nov; 32(11):1065-84. PubMed ID: 26578430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
    Prescrire Int; 2011 Feb; 20(113):33-7. PubMed ID: 21488586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
    Yang LP
    Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
    He YL; Serra D; Wang Y; Campestrini J; Riviere GJ; Deacon CF; Holst JJ; Schwartz S; Nielsen JC; Ligueros-Saylan M
    Clin Pharmacokinet; 2007; 46(7):577-88. PubMed ID: 17596103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
    Schwartz SL
    Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saxagliptin: a new drug for the treatment of type 2 diabetes.
    Thareja S; Aggarwal S; Malla P; Haksar D; Bhardwaj TR; Kumar M
    Mini Rev Med Chem; 2010 Jul; 10(8):759-65. PubMed ID: 20402634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.